Ayesha Naz, Zobia Jawad.
Comparison of role of Hydralazine Vs Labetalol in Mean Reduction of Mean Arterial Pressure in patients with Severe Preeclampsia.
Pak J Med Health Sci Jan ;13(2):259-62.

Aim: To compare the mean reduction in mean arterial pressure with the use of Hydralazine versus Labetalol in females presenting with severe preeclampsia. Study Design: Randomized Controlled Trial Setting: Unit I, Department of Obstetrics and Gynaecology, PGMI/Lahore General Hospital, Lahore. Duration of study: Six months after the approval of synopsis (July 26, 2016 till January 26, 2017) Methods:: 80 females who will fulfil the selection criteria were randomly divided into two equal groups by using lottery method, baseline MAP were recorded. In group A, females were given intravenous injection of Hydralazine 5mg bolus (slowly over 2 minutes) and after 15 minutes BP was recorded, if BP ≥ 160/110then second bolus of 5mg Hydralazine was given till maximum 4 boluses after every 15 minutes or attainment of BP 140/100. In group B, females was given intravenous injection Labetalol 20 mg at presentation, 40 mg after 10 minutes and 3 doses of 80 mg every 10 minutes (each bolus slowly over 2 minutes) till maximum 5 doses or attainment of BP 140/100. Females were followed-up in Labour room for 70 minutes and BP was recorded after every 10 minutes. Mean reduction in MAP was calculated (as per operational definition). Results: The mean age in Hydralazine and Labetalol groups were 30.62 +/- 6.22 years and 28.55 +/- 5.72 years. The mean gestational age in Hydralazine was 27.25 +/- 4.06 weeks and in Labetalol was 27.35 +/- 4.05 weeks. The mean number of doses in Hydralazine was 2.40 +/- 1.10 and in Labetalol was 2.42 +/- 0.96. The mean reduction in MAP in Hydralazine and Labetalol groups was 36.40 +/- 5.63 and 21.40 +/- 6.40. The mean reduction in MAP was significantly higher in hydralazine group, p-value < 0.001. Conclusion: Through the findings of this study we conclude that the mean reduction in MAP was significantly higher in Hydralazine than Labetalol groups. The reduction in MAP was not affected by age, parity, gestational age and number of doses when stratified for these variables.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com